July 26, 2018
IDO to I DON’T – IDO1 Inhibitor Development News
As targeted immuno-oncology agents make impressive strides in cancer treatment, researchers are looking for agents that can augment response or overcome patient resistance. While small molecule IDO1 (indoleamine 2,3-dioxygenase-1) inhibitors were an early favorite among commercial drug discovery programs, disappointing Phase 3 clinical trials drove a rapid ...
LEARN MORE
March 19, 2018
Targeting Myeloid Derived Suppressor Cells in Immuno-Oncology
Immune checkpoint inhibitors (ICIs) have dramatically changed the therapeutic approach to cancer, with antibodies ...
LEARN MORE
February 22, 2018
Tumor Infiltrating Lymphocytes: Conflicting Approaches in Immuno-Oncology
Today’s new frontier in cancer treatment is in fact a very, very old frontier indeed: tumor infiltrating lymphocytes ...
LEARN MORE
December 14, 2017
2017 Review: The Continued Rise of Immunotherapy
We CrownBio blog writers have been tasked with looking back at 2017 and reflecting on this year’s game changers in ...
LEARN MORE
November 20, 2017
Misidentified Cell Lines: The Scale of the Problem and How to Avoid It
Cell lines have been the cornerstone of life science research for decades. Yet they’ve been misidentified and misused ...
LEARN MORE
